138 related articles for article (PubMed ID: 1573338)
1. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
Mastrosimone F; Iaccarino C; de Caterina G
J Med; 1992; 23(1):1-16. PubMed ID: 1573338
[TBL] [Abstract][Full Text] [Related]
2. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
Siniatchkin M; Gerber WD; Vein A
Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
[TBL] [Abstract][Full Text] [Related]
6. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
[TBL] [Abstract][Full Text] [Related]
7. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study.
Brandes JL; Visser WH; Farmer MV; Schuhl AL; Malbecq W; Vrijens F; Lines CR; Reines SA;
Headache; 2004 Jun; 44(6):581-6. PubMed ID: 15186302
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
[TBL] [Abstract][Full Text] [Related]
9. [Long-term efficacy and side effects of various migraine prophylactics: a retrospective analysis.].
Haag G; Mastrosimone F; Iaccarino C; Müller MJ
Schmerz; 1994 Sep; 8(3):162-9. PubMed ID: 18415473
[TBL] [Abstract][Full Text] [Related]
10. [Double-blind clinical study: flunarizine versus pizotifen in a single nightly dose in hemicrania patients].
Cerbo R; Casacchia M; Formisano R; Buzzi MG; Boni B; Feliciani M; Grillo G; Cusimano G; Agnoli A
Riv Neurol; 1985; 55(2):139-46. PubMed ID: 4012191
[TBL] [Abstract][Full Text] [Related]
11. An extract of Petasites hybridus is effective in the prophylaxis of migraine.
Grossman W; Schmidramsl H
Altern Med Rev; 2001 Jun; 6(3):303-10. PubMed ID: 11410074
[TBL] [Abstract][Full Text] [Related]
12. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of cyclandelate versus flunarizine in the prophylactic treatment of migraine.
Nappi G; Sandrini G; Savoini G; Cavallini A; de Rysky C; Micieli G
Drugs; 1987; 33 Suppl 2():103-9. PubMed ID: 3304950
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
16. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of nimodipine in comparison with pizotifen in the prophylaxis of migraine.
Havanka-Kanniainen H; Hokkanen E; Myllylä VV
Cephalalgia; 1987 Mar; 7(1):7-13. PubMed ID: 3555838
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
20. Studies to assess if pizotifen prophylaxis improves migraine beyond the benefit offered by acute sumatriptan therapy alone.
Cleland PG; Barnes D; Elrington GM; Loizou LA; Rawes GD
Eur Neurol; 1997; 38(1):31-8. PubMed ID: 9252796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
